Innovation versus evidence: To trust direct-to-consumer personal genomic tests?

Expert Review of Molecular Diagnostics

Volumn 11, Issue 1, 2011, Pages 1-4

  Roukos, Dimitrios H ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

commercialization; evidence; genetics; genomics; human genome; innovation

Indexed keywords

CONSUMER; ENVIRONMENTAL FACTOR; GENE INTERACTION; GENETIC SCREENING; GENOME; GENOME ANALYSIS; HUMAN; REVIEW; RISK ASSESSMENT;

ENVIRONMENT; GENE EXPRESSION REGULATION; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PATIENT PARTICIPATION; PRIVATE SECTOR;

EID: 78650553804     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.99     Document Type: Review

References (38)

1. Collins F. Has the revolution arrived? Nature 464 (7289), 674-675 (2010).
2. Venter JC. Multiple personal genomes await. Nature 464 (7289), 676-677 (2010).
3. Shendure J, Ji H. Next-generation DNA sequencing. Nat. Biotechnol. 26, 1135-1145 (2008).
4. Roukos DH. Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark. Med. 4(4), 583-586 (2010).
5. Katsios C, Roukos DH. Individual genomes and personalized medicine: life diversity and complexity. Pers. Med. 7(4), 347-350 (2010).
6. Donnelly P. Progress and challenges in genome-wide association studies in humans. Nature 456, 728-731 (2008).
7. Manolio TA. Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363(2), 166-176 (2010).
8. Frazer KA, Ballinger DG, Cox DR et al; International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature 449(7164), 851-861 (2007).
9. Wacholder S, Hartge P, Prentice R et al. Performance of common genetic variants in breast-cancer risk models. N. Engl. J. Med. 362(11), 986-993 (2010).
10. Welch GH. Screening mammography - a long run for a short slide? N. Engl. J. Med. 363, 1276-1278 (2010).
11. Strope SA, Andriole GL. Prostate cancer screening: current status and future perspectives. Nat. Rev. Urol. 7(9), 487-493 (2010).
12. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 458(7239), 719-724 (2009).
13. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358(11), 1148-1159 (2008).
14. Katsnelson A. Genomics goes beyond DNA sequence. Nature 465(7295), 145 (2010).
15. Time for the epigenome. Nature 463(7281), 587 (2010).
16. Beaudet AL. Which way for genetic-test regulation? Leave test interpretation to specialists. Nature 466(7308), 816-817 (2010).
17. Evans JP, Dale DC, Fomous C. Preparing for a consumer-driven genomic age. N. Engl. J. Med. 363(12), 1099-1103 (2010).
18. Annes JP, Giovanni MA, Murray MF. Risks of presymptomatic direct-to-consumer genetic testing. N. Engl. J. Med. 363(12), 1100-1101 (2010).
19. Manolio TA, Collins FS, Cox NJ et al. Finding the missing heritability of complex diseases. Nature 461(7265), 747-753 (2009).
20. Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature 461(7261), 218-223 (2009).
21. Rockman MV. Reverse engineering the genotype-phenotype map with natural genetic variation. Nature 456, 738-744 (2008).
22. Roukos DH, Katsios C, Liakakos T. Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev. Mol. Diagn. 10(5), 541-545 (2010).
23. Roukos DH. Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3), 283-287 (2010).
24. Ng AC. Integrative systems biology and networks in autophagy. Semin. Immunopathol. DOI: 10.1007/s00281-010- 0225-9 (2010) (Epub ahead of print).
25. Friedman A, Perrimon N. Genetic screening for signal transduction in the era of network biology. Cell 128, 225-231 (2007).
26. Werner T. Next generation sequencing in functional genomics. Brief Bioinform. 11(5), 499-511 (2010).
27. Heard E, Tishkoff S, Todd JA et al. Ten years of genetics and genomics: what have we achieved and where are we heading? Nat. Rev. Genet. 11(10), 723-733 (2010).
28. Breitkreutz A, Choi H, Sharom JR et al. A global protein kinase and phosphatase interaction network in yeast. Science 328(5981), 1043-1046 (2010).
29. Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J. DOI:10.1038/tpj.2010.81 (2010) (Epub ahead of print).
30. Barnett GC, Shah M, Redman K, Easton DF, Ponder BA, Pharoah PD. Risk factors for the incidence of breast cancer: do they affect survival from the disease? J. Clin. Oncol. 26(20), 3310-3316 (2008).
31. Roukos DH. Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev. Mol. Diagn. 10(3), 247-250 (2010).
32. Wood SN. Statistical inference for noisy nonlinear ecological dynamic systems. Nature 466(7310), 1102-1104 (2010).
33. Via M, Gignoux C, Burchard EG. The 1000 Genomes Project: new opportunities for research and social challenges. Genome Med. 2(1), 3 (2010).
34. International Cancer Genome Consortium. International network of cancer genome projects. Nature 464, 993-998 (2010).
35. Katsnelson A. Genomics goes beyond DNA sequence. Nature 465(7295), 145 (2010).
36. Roukos DH. Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev. Med. Devices 7(6), 723-726 (2010).
37. Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev. Mol. Diagn. 10(1), 33-48 (2010)
38. The human genome at ten. Nature 464(7289), 649-650 (2010).